Image Place holder

Hatem Soliman, MD

Medical Director of the Clinical Trials Office

Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt McKinley Outpatient Center
Overview

Cancer Types Treated: Breast Cancer, Ductal Carcinoma In Situ , Inflammatory Breast Cancer , Invasive Ductal Carcinoma , Triple Negative Breast Cancer

Dr. Hatem Soliman is a medical oncologist specializing in breast cancer in The Center for Women’s Oncology at Moffitt Cancer Center.  He treats women with all stages of breast cancer, from early disease to locally advanced, as well as metastatic breast cancers.  Dr. Soliman is a member of the Experimental Therapeutics Program at Moffitt and participates in research on novel drug discoveries. His interest in cancer research dates back to his undergraduate studies in genetics at the University of Georgia, where he won the prestigious Howard Hughes Summer Research Grant.  While attending Medical College of Georgia, he was awarded a research fellowship grant and participated in a National Cancer Institute-sponsored study evaluating a new immune-stimulating vaccine for breast cancer.  Dr. Soliman continues to study vaccine therapies during his research activities at Moffitt. Dr. Soliman has a strong interest in community service and volunteers at the Red Crescent Clinic in Tampa, providing primary health care services to people who are indigent or underinsured.  Dr. Soliman is fluent in Arabic.

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • University of South Florida - Hematology/Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • Medical College of Georgia - MD
Participating Trials

CLINICAL TRIAL 18621
A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Condition:
Intervention: Adriamycin (doxorubicin); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 19340
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Condition:
Intervention: Herceptin (Trastuzumab); Not Applicable; Placebo; Trastuzumab; Tucatinib; Xeloda (capecitabine); capecitabine; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 19337
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Condition:
Intervention: DC1 Vaccine; Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab; Taxotere (docetaxel); Trastuzumab; carboplatin; docetaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition:
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19105
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)
Condition:
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab); PVX-410
Open

CLINICAL TRIAL 18356
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Condition:
Intervention:
Open

CLINICAL TRIAL 18386
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Condition:
Intervention: Not Applicable
Open

CLINICAL TRIAL 18862
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer
Condition:
Intervention: Herceptin (Trastuzumab); SGN-LIV1A; Trastuzumab; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition:
Intervention:
Open

CLINICAL TRIAL 18596
A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy
Condition:
Intervention: Not Applicable
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition:
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18810
Phase 1b Study To Assess The Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole Or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (Mbc)
Condition:
Intervention: 772256 (Palbociclib); Faslodex (fulvestrant); Femara (Letrozole); Gedatolisib; Letrozole; PF-05212384 (Gedatolisib); Palbociclib; fulvestrant
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition:
Intervention:
Open

CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition:
Intervention: Not Applicable; TSR-033; TSR-042
Open

CLINICAL TRIAL 19328
SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy
Condition:
Intervention: Faslodex (fulvestrant); Not Applicable; Placebo; Seribantumab; fulvestrant
Open

CLINICAL TRIAL 16664
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Metastatic and Locally Advanced Breast Cancer
Condition:
Intervention: Adriamycin (doxorubicin); Taxol (paclitaxel); Triciribine (TCN-PM (0002)); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition:
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition:
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 19393
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage,Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Condition:
Intervention: Abemaciclib; LY2835219 (Abemaciclib)
Open

CLINICAL TRIAL 19394
An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2-Negative, Brca-Mutant Breast Cancer Patients
Condition:
Intervention: Niraparib
Open

CLINICAL TRIAL 19603
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Condition:
Intervention: Pembrolizumab (Keytruda); SGN-LIV1A
Open

CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Nktr-214 And In combination With Nktr-214 Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Condition:
Intervention: BMS-936558 (Nivolumab); NKTR-214; NKTR-262; Nivolumab
Open

CLINICAL TRIAL 19497
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
Condition:
Intervention: MLN4924 (Pevonedistat); Paraplatin (carboplatin); Pevonedistat; Taxol (paclitaxel); Taxotere (docetaxel); carboplatin; docetaxel; paclitaxel
Open

CLINICAL TRIAL 19228
A Phase 2, Multi-Center, Open Label Study of NIR178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin lymphoma
Condition:
Intervention: NIR178; Not Applicable; PDR001
Open

CLINICAL TRIAL 18979
Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
Condition:
Intervention: Atezolizumab (Tecentriq); Olaparib (Lynparza)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Mar;16(3):310-320. Pubmedid: 29523670.
  • B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun;169(2):391-396. Pubmedid: 29392582.
  • Chen YZ, Kim Y, Soliman H, Ying G, Lee JK. Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy. Endocr Relat Cancer. 2018 Jun;25(6):595-605. Pubmedid: 29599124. Pmcid: PMC5920016.
  • Ahmed KA, Grass GD, Orman AG, Liveringhouse C, Montejo ME, Soliman HH, Han HS, Czerniecki BJ, Torres-Roca JF, Diaz R. Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. Int J Breast Cancer. 2018 Jun;2018:6729802. Pubmedid: 29984003. Pmcid: PMC6015692.
  • Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay. JAMA Oncol. 2018 Jan;4(1):e173470. Pubmedid: 29075751. Pmcid: PMC5833645.
  • de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 2018 Jan;33(1):60-74.e6. Pubmedid: 29316433. Pmcid: PMC5764109.
  • Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, Antonia S. A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer. Oncotarget. 2018 Feb;9(11):10110-10117. Pubmedid: 29515795. Pmcid: PMC5839376.
  • Cox K, Alford B, Soliman H. Emerging Therapeutic Strategies in Breast Cancer. South Med J. 2017 Oct;110(10):632-637. Pubmedid: 28973703.
  • Tauro M, Shay G, Sansil SS, Laghezza A, Tortorella P, Neuger AM, Soliman H, Lynch CC. Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Mol Cancer Ther. 2017 Mar;16(3):494-505. Pubmedid: 28069877. Pmcid: PMC5337166.
  • Prabhakaran S, Rizk VT, Ma Z, Cheng CH, Berglund AE, Coppola D, Khalil F, Mulé JJ, Soliman HH. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. Breast Cancer Res. 2017 Jun;19(1):71. Pubmedid: 28629479. Pmcid: PMC5477261.
  • Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res. 2017 Jun;19(1):75. Pubmedid: 28666457. Pmcid: PMC5493088.
  • Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, André F. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017 Feb;19(1):18. Pubmedid: 28183331. Pmcid: PMC5301372.
  • Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S. Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat. J Adolesc Young Adult Oncol. 2017 Dec;6(4):503-511. Pubmedid: 28777007. Pmcid: PMC5725631.
  • Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives. Cancer Treat Rev. 2017 Dec;61:107-115. Pubmedid: 29125981.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Ne. 2017 Apr;15(4):433-451. Pubmedid: 28404755.
  • George B, Kelly K, Ko A, Soliman H, Trunova N, Wainberg Z, Waterhouse D, O'Dwyer P. P1.46: Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct;11(10S):S211-S212. Pubmedid: 27676532.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Mar;14(3):324-354. Pubmedid: 26957618.
  • Yardley DA, Reeves J, Dees EC, Osborne C, Paul D, Ademuyiwa F, Soliman H, Guthrie T, Andersen J, Krekow L, Choksi J, Daniel B, Danso M, Favret A, Oommen S, Brufsky A, Bromund JL, Lin Y, Ibrahim AB, Richards PD. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clin Breast Cancer. 2016 Dec;16(6):471-479.e1. Pubmedid: 27569274.
  • Soliman HH. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther. 2016 Dec;10:101-112. Pubmedid: 28053544. Pmcid: PMC5189972.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Yang L, Song T, Chen L, Soliman H, Chen J. Nucleolar repression facilitates initiation and maintenance of senescence. Cell Cycle. 2015 Nov;14(22):3613-3623. Pubmedid: 26505814. Pmcid: PMC4825723.
  • Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ. Propelling Immunotherapy Combinations Into the Clinic. Oncology (Williston Park). 2015 Dec;29(12):990-1002. Pubmedid: 26680224.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Ne. 2015 Dec;13(12):1475-1485. Pubmedid: 26656517.
  • Soliman H, Mediavilla-Varela M, Antonia SJ. A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. Breast Cancer (Dove Med Press). 2015 Dec;7:389-397. Pubmedid: 26719725. Pmcid: PMC4687618.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer Version 2.2015. J Natl Compr Canc Ne. 2015 Apr;13(4):448-475. Pubmedid: 25870381.
  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557. Pmcid: PMC4226672.
  • Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse DL. The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition. Front Immunol. 2014 Oct;5:429. Pubmedid: 25368611. Pmcid: PMC4202790.
  • Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One. 2014 Feb;9(2):e88557. Pubmedid: 24551119. Pmcid: PMC3925108.
  • Menanteau-Ledouble S, Soliman H, Kumar G, El-Matbouli M. Use of in vivo induced antigen technology to identify genes from Aeromonas salmonicida subsp. salmonicida that are specifically expressed during infection of the rainbow trout Oncorhynchus mykiss. BMC Vet Res. 2014 Dec;10:298. Pubmedid: 25495705. Pmcid: PMC4269963.
  • Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Ne. 2014 Apr;12(4):542-590. Pubmedid: 24717572.
  • Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, Antonia S. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013 Sep;14(9):860-868. Pubmedid: 23917542. Pmcid: PMC3909555.
  • Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immun. 2013 May;62(5):829-837. Pubmedid: 23344392. Pmcid: PMC4501769.
  • Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013 Mar;2(3):e23428. Pubmedid: 23802083. Pmcid: PMC3661168.
  • Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2013 Jul;11(7):753-760. Pubmedid: 23847214. Pmcid: PMC3991132.
  • Soliman H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control. 2013 Jan;20(1):17-21. Pubmedid: 23302903.
  • Joh JE, Esposito NN, Kiluk JV, Laronga C, Khakpour N, Soliman H, Catherine Lee M. Pathologic Tumor Response of Invasive Lobular Carcinoma to Neo-adjuvant Chemotherapy. Breast J. 2012 Nov;18(6):569-574. Pubmedid: 23034096.
  • Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist. 2012 Jun;16(11):1520-1526. Pubmedid: 22016474. Pmcid: PMC3233285.
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012 Jul;10(7):821-829. Pubmedid: 22773798. Pmcid: PMC3753191.
  • Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-991. Pubmedid: 20420527. Pmcid: PMC3146364.
  • Soliman H. Developing an effective breast cancer vaccine. Cancer Control. 2010 Jul;17(3):183-190. Pubmedid: 20664516.
  • Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor?. Cancer J. 2010 Jul;16(4):354-359. Pubmedid: 20693847. Pmcid: PMC3850167.
  • Soliman H, Ferrari A, Thomas D. Sarcoma in the young adult population: an international view. Semin Oncol. 2009 Jun;36(3):227-236. Pubmedid: 19460580.
  • Soliman H, Agresta S. Current issues in adolescent and young adult cancer survivorship. Cancer Control. 2008 Jan;15(1):55-62. Pubmedid: 18094661.
  • Ling J, Pi W, Bollag R, Zeng S, Keskintepe M, Soliman H, Krantz S, Whitney B, Tuan D. The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells. J Virol. 2002 Mar;76(5):2410-2423. Pubmedid: 11836419.